We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
268 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBREVANT SC amivantamab 1600mg/10mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBREVANT SC amivantamab 2240mg/14mL solution for injection vial.
-
Australian public assessment report (AusPar)Lazcluze (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPSUMIT macitentan 2.5 mg dispersible tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 200 mg / 2 mL solution for injection, pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 200 mg / 2 mL solution for injection, pre-filled pen (auto-injector).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 200 mg / 20 mL concentrated solution for intravenous infusion, vial.
-
Sep-2025Prescription medicine evaluationActive ingredient: ibrutinib.
-
-
Australian public assessment report (AusPar)TALVEY (talquetamab) has been provisionally approved for the treatment of adult patients with relapsed or refractory multiple myeloma.